双歧杆菌乳杆菌三联活菌片对肝硬化自发性腹膜炎患者肠黏膜屏障功能的保护作用

目的探讨双歧杆菌乳杆菌三联活菌片对肝硬化自发性腹膜炎（SBP）患者肠黏膜屏障功能的保护作用。方法选取乙肝后肝硬化SBP患者68例,随机分为观察组和对照组各34例。两组患者均予以保肝利尿、降血氨、降低门脉压、抗感染、补充白蛋白和营养支持等常规治疗。观察组患者加用双歧杆菌乳杆菌三联活菌片2.0 g/次,2次/d,连用2周。对照组患者除不使用双歧杆菌乳杆菌三联活菌片余治疗同观察组。观察两组患者治疗前后血清DAO和D-Lac水平的变化,并比较临床疗效。结果治疗2周后,两组患者血清DAO和D-Lac水平均较前明显下降（P〈0.05或P〈0.01）,且观察组下降值明显大于对照组（P〈0.05）;同时观察组患者的临床总有效率（94.12%）明显高于对照组（73.53%）（χ2=5.31,P〈0.05）。结论双歧杆菌乳杆菌三联活菌片辅助治疗肝硬化SBP患者具有较好疗效,具有良好肠黏膜屏障保护功能。

Protective effect of Live Combined Bifidobacterium and Lactobacillus Bacteria Tablets on intestinal mucosal barrier of patients with spontaneous peritonitis in cirrhosis

Objective To discuss the protective effect of Live Combined Bifidobacterium and Lactobaeillus Bacteria Tablets on intestinal mueosal barrier of patients with spontaneous peritonitis （SBP） in cirrhosis. Methods 68 cases of patients with SBP in cirrhosis after from suffering hepatitis B were selected and divided into observation group and control at random, with 34 cases of patients in either group. The patients in both groups were given routine medical treatments, such as liver protection, diuresis, lowering blood ammonia and portal pressure, anti-infection, albumin supplement, nutrition support etc. The patients in observation group were additionally given Live Combined Bifidobacterium and Lactobacillus Bacteria Tablets 2.0 g per time, twice a day for 2 weeks. The changes of serum DAO and D-Lac levels of patients in both groups before and after medical treatment were observed, and the clinical curative effects were compared as well. Results After 2 weeks＇ medical treatment, the serum DAO and D-Lac levels of patients in both groups obviously declined than before （P 〈0.05 or P 〈0.01 ） , and the declining rate in observation group was much higher than that in control group （ P 〈 0.05 ）. Meanwhile, the total clinical efficiency in observation group （94.12%） was much higher than that in control group （73.53%） （X2 =5.31, P 〈 0.05 ）. Conclusion Live Combined Bifidobacterium and Lactobacillus Bacteria Tablets has reliable curative effects on patients with SBP in cirrhosis as adjunctive therapy （AT） , which has favorable protective effect on intes- tinal mucosal barrier.